echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Sci Advs: Study finds new drug for rheumatoid arthritis

    Sci Advs: Study finds new drug for rheumatoid arthritis

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 19, 2022, Zhang Tiantai's research group, Sun Lan's research group and Zhang Dayong's research group of China Pharmaceutical University published in the journal Science Advances "Science Advances".


    Rheumatoid arthritis (RA) is a chronic systemic disease with unknown etiology, mainly inflammatory synovitis, which can cause joint deformity and loss of function


    Aiming at targeting JAK3 isoforms, the research team designed, synthesized, and screened to obtain a lead compound Z583 that inhibits JAK3 phosphorylation with IC50 of 0.


    Paper link:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.